⌕
TG Therapeutics · TGTX · Nasdaq
Tenet 45 · Mixed
Compare
$64.51−0.08%At closeTenet 45 · Mixed
$64.51−0.05 (−0.08%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

TG Therapeutics (TGTX) Stock

TG Therapeutics (TGTX) closed at $64.51 on Nov 13, 2026; its Tenet Score is 45 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

9 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$64.51
Nov 13, 2026
Market cap
$9.9B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
23.0×
price ÷ earnings
52-week range
26.76 – 68.03
low → high
Tenet Score
45/100
Mixed · 409 Healthcare peers

Industry: Drugs · see every company filed here →

TG Therapeutics Inc scores 45/100. Mixed. Strongest on quality, value is the soft spot, trading at 23× earnings versus 409 Healthcare peers. Insufficient inputs: Tenet 45 is built from 3 of 4 pillars, from 90% of its inputs. Growth is left out because no growth rate could be measured.

Tenet Score · vs sector

n=409
45/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
20
Quality
70
Health
46
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueFQualityBHealthDGrowth—MomentumA
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
16.3×
price to book value
P/S
12.4×
price to fiscal 2025 sales
ROE
100%
return on equity
Operating margin
20.0%
fiscal 2025, before interest and tax
Net margin
55.2%
of revenue kept
Current ratio
4.27
current assets to liabilities
Net debt / EBITDA
1.4×
leverage, net of cash
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab,…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 131 US ETFs · top wrappers by weightSee all ETFs holding TGTX →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is TG Therapeutics in?

TG Therapeutics is in the Healthcare sector and the Drugs industry.

What is TG Therapeutics' Tenet Score?

TG Therapeutics' Tenet Score is 45 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.